Overview

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

Status:
Terminated

Trial end date:
2013-08-01

Target enrollment:
0

Participant gender:
All

Summary

This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Criteria

Inclusion Criteria:

- Diagnosis of probable Alzheimer Disease (AD), with Mini Mental State Examination
(MMSE) score of 16-26, and brain magnetic resonance imaging (MRI) consistent with the
diagnosis of AD

- Concurrent use of cholinesterase inhibitor or memantine allowed, if stable

- Caregiver will participate and be able to attend clinic visits with patient

Exclusion Criteria:

- Significant neurological disease other than AD

- Major psychiatric disorder

- Contraindication to undergo brain MRI [e.g., pacemaker, cerebrospinal fluid (CSF)
shunt, or foreign metal objects in the body]

- Women of childbearing potential